Little House Capital LLC Acquires 13,304 Shares of Johnson & Johnson $JNJ

Key Points

• Little House Capital LLC increased its holdings in Johnson & Johnson by 46.3%, acquiring an additional 13,304 shares in the second quarter, bringing its total to 42,015 shares.
• Johnson & Johnson reported earnings of $2.77 per share for the last quarter, surpassing analysts' expectations by $0.09, with total revenue reaching $23.74 billion.
• The company announced a quarterly dividend of $1.30 per share, resulting in an annualized dividend yield of 2.9% and a payout ratio of 55.61%.

Little House Capital LLC increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 46.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,015 shares of the company's stock after purchasing an additional 13,304 shares during the quarter. Johnson & Johnson makes up 1.6% of Little House Capital LLC's investment portfolio, making the stock its 20th biggest holding. Little House Capital LLC's holdings in Johnson & Johnson were worth $6,418,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at $47,000. 1248 Management LLC bought a new stake in Johnson & Johnson in the first quarter valued at $48,000. von Borstel & Associates Inc. bought a new stake in Johnson & Johnson in the first quarter valued at $49,000. Finally, Capital A Wealth Management LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $50,000. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on JNJ. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Citigroup lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, August 21st. Royal Bank Of Canada lifted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Finally, Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Stock Down 0.3%

JNJ opened at $177.49 on Tuesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a market cap of $427.46 billion, a price-to-earnings ratio of 18.98, a PEG ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The company's 50-day moving average price is $171.25 and its two-hundred day moving average price is $161.36.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.